SK17142000A3 - Hydrochlorid paroxetínu vo forme inej než hemihydrát formulovaný do tabliet, spôsob výroby tabliet hydrochloridu paroxetínu a súprava zahrnujúca takéto tablety - Google Patents

Hydrochlorid paroxetínu vo forme inej než hemihydrát formulovaný do tabliet, spôsob výroby tabliet hydrochloridu paroxetínu a súprava zahrnujúca takéto tablety Download PDF

Info

Publication number
SK17142000A3
SK17142000A3 SK1714-2000A SK17142000A SK17142000A3 SK 17142000 A3 SK17142000 A3 SK 17142000A3 SK 17142000 A SK17142000 A SK 17142000A SK 17142000 A3 SK17142000 A3 SK 17142000A3
Authority
SK
Slovakia
Prior art keywords
paroxetine
anhydrous
paroxetine hydrochloride
hemihydrate
tablets
Prior art date
Application number
SK1714-2000A
Other languages
English (en)
Slovak (sk)
Inventor
David Philip Elder
Graham Stanley Leonard
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of SK17142000A3 publication Critical patent/SK17142000A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SK1714-2000A 1998-05-13 1999-05-13 Hydrochlorid paroxetínu vo forme inej než hemihydrát formulovaný do tabliet, spôsob výroby tabliet hydrochloridu paroxetínu a súprava zahrnujúca takéto tablety SK17142000A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9810181.9A GB9810181D0 (en) 1998-05-13 1998-05-13 Novel formulations
PCT/GB1999/001520 WO1999058113A2 (en) 1998-05-13 1999-05-13 Novel formulation containing paroxetine

Publications (1)

Publication Number Publication Date
SK17142000A3 true SK17142000A3 (sk) 2001-06-11

Family

ID=10831927

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1714-2000A SK17142000A3 (sk) 1998-05-13 1999-05-13 Hydrochlorid paroxetínu vo forme inej než hemihydrát formulovaný do tabliet, spôsob výroby tabliet hydrochloridu paroxetínu a súprava zahrnujúca takéto tablety

Country Status (20)

Country Link
EP (1) EP1077682A2 (id)
JP (1) JP2002514591A (id)
KR (1) KR20010043574A (id)
CN (1) CN1308521A (id)
AP (1) AP2000002019A0 (id)
AU (1) AU3940999A (id)
BG (1) BG105010A (id)
BR (1) BR9910401A (id)
CA (1) CA2331871A1 (id)
EA (1) EA200001174A1 (id)
GB (1) GB9810181D0 (id)
HU (1) HUP0102064A2 (id)
ID (1) ID28019A (id)
IL (1) IL139594A0 (id)
NO (1) NO20005683L (id)
PL (1) PL344573A1 (id)
SK (1) SK17142000A3 (id)
TR (1) TR200003350T2 (id)
WO (1) WO1999058113A2 (id)
ZA (1) ZA200006562B (id)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
NZ532432A (en) * 2001-10-22 2005-02-25 Synthon Bv N-formyl paroxetine compounds and their use in a synthetic route for obtaining paroxetine
GB2636182A (en) * 2023-12-04 2025-06-11 Novumgen Ltd An orally disintegrating tablet of paroxetine and its process of preparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5672612A (en) * 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
EP0952831A1 (en) * 1997-01-15 1999-11-03 Smithkline Beecham Plc Paroxetine compositions
CA2315088A1 (en) * 1997-12-19 1999-07-01 Smithkline Beecham Corporation Process for manufacturing bite-dispersion tablets

Also Published As

Publication number Publication date
WO1999058113A2 (en) 1999-11-18
TR200003350T2 (tr) 2001-03-21
IL139594A0 (en) 2002-02-10
ZA200006562B (en) 2002-02-13
CA2331871A1 (en) 1999-11-18
EP1077682A2 (en) 2001-02-28
WO1999058113A3 (en) 2000-02-17
PL344573A1 (en) 2001-11-05
EA200001174A1 (ru) 2001-06-25
CN1308521A (zh) 2001-08-15
JP2002514591A (ja) 2002-05-21
AP2000002019A0 (en) 2000-12-31
BR9910401A (pt) 2001-01-09
HUP0102064A2 (hu) 2002-05-29
BG105010A (en) 2001-07-31
KR20010043574A (ko) 2001-05-25
NO20005683D0 (no) 2000-11-10
ID28019A (id) 2001-05-03
GB9810181D0 (en) 1998-07-08
NO20005683L (no) 2000-12-05
AU3940999A (en) 1999-11-29

Similar Documents

Publication Publication Date Title
US6368627B1 (en) Compositions
WO2009024889A2 (en) Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
HRP20030527A2 (en) Pharmaceutical compositions comprising amlodipinemaleate
SK6102001A3 (en) Pharmaceutical moxifloxacin preparation
US20080305158A1 (en) Methods For the Preparation of Stable Pharmaceutical Solid Dosage Forms of Atorvastatin and Amlodipine
EP2233133B1 (en) Stable Rosuvastatin Compositions
SK17142000A3 (sk) Hydrochlorid paroxetínu vo forme inej než hemihydrát formulovaný do tabliet, spôsob výroby tabliet hydrochloridu paroxetínu a súprava zahrnujúca takéto tablety
PL191767B1 (pl) Stabilizowane przed racemizacją stałe lub ciekłe preparaty farmaceutyczne zawierające jako składnik czynny cilansetron, sposób wytwarzania stabilizowanych przed racemizacją stałych preparatów farmaceutycznych zawierających jako składnik czynny cilansetron oraz zastosowanie dopuszczalnych fizjologicznie rozpuszczalnych w wodzie kwaśnych dodatków
US20040157925A1 (en) Stable pharmaceutical composition of pravastatin
IE44427B1 (en) A pharmaceutically active benzothiadiazole derivative
EP1968593B1 (en) Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
WO2004091624A1 (en) Combinations comprising paroxetine and 2- (s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-carboxylic acid [1- (r)- (3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide for treatment of depression and/or anxiety
KR20170083484A (ko) 용출률이 개선된 네비보롤을 포함하는 약학적 조성물
CA2399411A1 (en) Water dispersible formulation of paroxetine
AU754765B2 (en) Paroxetine compositions
US20060270715A1 (en) Dosage forms of amlodipine and processes for their preparation
KR20010105418A (ko) 기분 장애 치료용 오사네턴트
US20060216345A1 (en) Oral pharmaceutical composition including paroxetine
MXPA00011154A (en) Novel formulation containing paroxetine
AU2007355452B2 (en) Improved pharmaceutical formulation containing an HMG-CoA reductase inhibitor and method for the preparation thereof
US20080206328A1 (en) Hypocholesterolemic Compositions Comprising a Statin and an Antiflatulent Agent
CZ20004186A3 (cs) Nový prostředek obsahující paroxetin
US20040131672A1 (en) Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
KR102441089B1 (ko) 의약 조성물
RU2780646C1 (ru) Новая кристаллическая форма 7-бром-1-(гидразинокарбонил)метил-5-фенил-1,2-дигидро-3h-1,4-бензодиазепин-2-она и ее фармацевтическое применение